Latest Breaking News On - Chief executive officer rob davis - Page 1 : comparemela.com

Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar

Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Rob davisPrometheus biosciences incAcceleron pharma incDaiichi sankyo coBloomberg merck coHarpoon therapeutics incDaiichi sankyoChief executive officer rob davisAcceleron pharma

Merck Drug for Rare Form of High Blood Pressure Gets US Nod

Merck Drug for Rare Form of High Blood Pressure Gets US Nod
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

United statesAcceleron pharmaCarlos santos gallegoRob davisEvan seigermanRobert langrethUnited therapeutics corpDrug administrationIcahn school of medicine at mount sinaiBristol myers squibb coBloomberg merck coTherapeutics corpIcahn schoolMount sinaiChief executive officer rob davisNew england journal

Merck Cancer Drug Keytruda Drives Sales Past Street Estimates

Merck Cancer Drug Keytruda Drives Sales Past Street Estimates
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesTom contilianoRob davisDaiichi sankyoPfizer incPrometheus biosciences incDaiichi sankyo coHarpoon therapeutics incBloomberg merck coWall streetHarpoon therapeuticsChief executive officer rob davisNew jersey based

Ozempic Challengers, Immunology Firms Line Up for Rebound in M&A

Ozempic Challengers, Immunology Firms Line Up for Rebound in M&A
themiddlemarket.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themiddlemarket.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesBrad loncarRob davisNick shipleyMike gaitoEric tokatJapan daiichi sankyo coSeagen incKaruna therapeutics incJpmorgan chase coMerck coImmunovant incPrometheus biosciences incGilead sciences incRoche holding

Ozempic challengers, immunology firms line up for rebound in M&A

Biotech investors are heading into the year s biggest dealmaking event with a renewed sense of optimism after more than two years of layoffs and shrin.

San franciscoUnited statesNick shipleyEric tokatBrad loncarRob davisMike gaitoBristol myers squibb coRoche holdingPrometheus biosciences incImmunovant incPfizer incKaruna therapeutics incCarmot therapeutics incAbbvie incImmunogen inc